Form 4 Filing for ARS Pharmaceuticals, Inc.

Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, Inc., reported a series of transactions on June 12, 2026. Karas acquired 25,000 shares of Common Stock under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025, and exercised a stock option to acquire 25,000 shares of Common Stock. He also sold 25,000 shares of Common Stock pursuant to a Rule 10b5-1 trading plan. The reported transactions resulted in post-transaction ownership of 37,176 shares acquired under the ESPP and 12,176 shares sold from his holdings. The stock option, exercisable immediately, has an exercise price of $1.50 and an expiration date of May 23, 2032. This filing is classified as an OFFICER_DIRECTOR_CHANGE due to the nature of the transactions reported by an executive officer.